A new drug has been hailed as a scientific breakthrough in treating Alzheimer’s disease, following the publication of final trial results in the medical journal, JAMA.  The findings show donanemab can successfully slow down decline in memory and thinking by 35 per cent among people with early-stage Alzheimer’s Disease. The drug’s ability to slow down […]

The findings of a research study that discovered a treatment for early stage Alzheimer’s disease have been hailed as “momentous” by Alzheimer’s Research UK.  The new treatment, lecanemab, is the first drug to slow cognitive decline in people with early signs of the condition. The CLARITY-AD study enrolled 1,795 patients with early-stage Alzheimer’s globally, including Join […]

A research study exploring the impact specialist anti-inflammatory drugs have on Alzheimer’s disease symptoms is looking for volunteers in London, Plymouth, Guildford and Southampton. The EXploratory PLatform trial on Anti-INflammatory agents in Alzheimer’s Disease, or EXPLAIN-AD for short, will be evaluating the effectiveness and safety of anti-inflammatory agents on common Alzheimer’s symptoms – including memory, […]

News that a potential treatment for early stage Alzheimer’s disease can slow cognitive decline is a significant development in dementia research. About the drug Lecanemab is an antibody that is designed to remove toxic beta-amyloid deposits; proteins that build up in the brains of people with Alzheimer’s disease. Following phase 3 clinical trials, pharmaceutical companies […]

There are almost one million people with dementia in the UK and the most common cause is Alzheimer’s disease. Researchers from University College London (UCL) with funding from the National Institute for Health and Care Research are testing a new approach to the treatment of mild Alzheimer’s disease in the DESPIAD (DEpletion of SaP in […]

After a period of many online studies, we are pleased to share that researchers are increasingly inviting participants to take part in face to face studies.  Here are some examples of studies currently looking for volunteers to take part in different parts of the UK: Sleep, gut health and cognition study Insomnia in later life […]

Alzheimer’s disease is the most common cause of dementia in the UK and the symptoms develop gradually over many years. Background The symptoms of Alzheimer’s disease can progress slowly and many, such as getting more forgetful, can be attributed to ‘just getting older.’ This can make diagnosis more difficult and currently there is no single […]

All medicines may have side effects for the people who take them. But if there was a new treatment to slow or stop Alzheimer’s, how would you weigh up its benefits against its potential risks? That’s what researchers are asking as part of a new project. One of our charity partners, Alzheimer’s Research UK, has […]

An opinion piece by Professor John O’Brien, NIHR Clinical Research Network National Specialty Lead for Dementias The European Medicines Agency (EMA) has today said no to approving aducanumab – a new drug to treat Alzheimer’s disease. EMA considered that although the drug removed amyloid, a toxic protein that builds up in the brains of people […]

The possible link between air pollution and dementia has been a focus of several studies and at the recent US Alzheimer’s Association International Conference (AAIC), the topic came to the fore again.  New findings Whilst previous reports have linked long-term air pollution exposure with accumulation of Alzheimer’s disease-related brain plaques, a series of new reports […]